An opportunity lost: HIV infections associated with lack of a National needle-exchange programme in the USA

Center for AIDS Prevention Studies, University of California, San Francisco 94105, USA.
The Lancet (Impact Factor: 45.22). 04/1997; 349(9052):604-8. DOI: 10.1016/S0140-6736(96)05439-6
Source: PubMed


Our aim was to estimate the number of HIV infections that could have been prevented had needle-exchange programmes been implemented during the early stages of the AIDS epidemic in the USA. We also estimated the cost to the US health-care system to treat these preventable HIV infections.
The formula we used to calculate the annual number of preventable HIV infections accounted for the effectiveness and level of use of needle-exchange programmes, as well as sexual transmission to injection drug users (IDUs) and secondary transmission to their sexual partners and children. Data for the model were obtained from epidemiological and mathematical studies in peer-reviewed published research, government reports, and consultations with experts. Using data from Australia as a model, we calculated the number of HIV infections that could have been prevented by a national needle-exchange programme in the USA between 1987 and 1995. Cost calculations were based on the current US government estimate of the discounted lifetime cost of treating an HIV infection (US $55640).
Our conservative calculation of the number of HIV infections that could have been prevented ranged from 4394 (15% incidence reduction due to needle exchanges) to 9666 (33% incidence reduction). The cost to the US health-care system of treating these preventable HIV infections is between US $244 million and US $538 million, respectively. If current US policies are not changed, we estimate that an additional 5150-11329 preventable HIV infections could occur by the year 2000.
The failure of the federal government in the USA to implement a national needle-exchange programme, despite six government-funded reports in support of needle exchanges, may have led to HIV infection among thousands of IDUs, their sexual partners, and their children. Revoking the US government ban on funding for needle-exchange programmes and accelerating the growth of such programmes in the USA are urgent public-health priorities.

1 Follower
13 Reads
  • Source
    • "It is important to note that the calculated cost-savings of Insite are an under-estimate of the actual cost-savings. In our analyses, we do not consider any growth of the PWID population [15], new secondary HIV and HCV infections [44,45], or any reductions in other harms such as cellulitis, subcutaneous abscesses, endocarditis, and other soft-tissue infections [44]. Perhaps, more significant is the fact that we do not consider the value of a prevented death. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Supervised injection facilities (SIFs) are venues where people who inject drugs (PWID) have access to a clean and medically supervised environment in which they can safely inject their own illicit drugs. There is currently only one legal SIF in North America: Insite in Vancouver, British Columbia, Canada. The responses and feedback generated by the evaluations of Insite in Vancouver have been overwhelmingly positive. This study assesses whether the above mentioned facility in the Downtown Eastside of Vancouver needs to be expanded to other locations, more specifically that of Canada’s capital city, Ottawa. Methods The current study is aimed at contributing to the existing literature on health policy by conducting cost-benefit and cost-effective analyses for the opening of SIFs in Ottawa, Ontario. In particular, the costs of operating numerous SIFs in Ottawa was compared to the savings incurred; this was done after accounting for the prevention of new HIV and Hepatitis C (HCV) infections. To ensure accuracy, two distinct mathematical models and a sensitivity analysis were employed. Results The sensitivity analyses conducted with the models reveals the potential for SIFs in Ottawa to be a fiscally responsible harm reduction strategy for the prevention of HCV cases – when considered independently. With a baseline sharing rate of 19%, the cumulative annual cost model supported the establishment of two SIFs and the marginal annual cost model supported the establishment of a single SIF. More often, the prevention of HIV or HCV alone were not sufficient to justify the establishment cost-effectiveness; rather, only when both HIV and HCV are considered does sufficient economic support became apparent. Conclusions Funded supervised injection facilities in Ottawa appear to be an efficient and effective use of financial resources in the public health domain.
    Substance Abuse Treatment Prevention and Policy 08/2014; 9(31). DOI:10.1186/1747-597X-9-31 · 1.16 Impact Factor
  • Source
    • "Policymakers are increasingly acknowledging the harmful consequences of drug prohibition [1]. Punitive drug policies have largely failed to reduce the prevalence of drug abuse [2], fuelled epidemics of HIV and hepatitis C virus (HCV) infection [3-6], and discouraged the implementation and use of needle/syringe exchange programs, opioid substitution treatment (e.g., methadone maintenance), and other evidence-based public health interventions [7,8]. Law enforcement and policing activities that typically accompany drug control initiatives also result in the criminalization and stigmatization of drug users [9,10], high incarceration rates [11,12], human rights abuses [13,14], and escalations in drug-related violence and corruption leading to considerable political instability [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Policymakers and researchers seek answers to how liberalized drug policies affect people who inject drugs (PWID). In response to concerns about the failing "war on drugs," Mexico recently implemented drug policy reforms that partially decriminalized possession of small amounts of drugs for personal use while promoting drug treatment. Recognizing important epidemiologic, policy, and socioeconomic differences between the United States--where possession of any psychoactive drugs without a prescription remains illegal--and Mexico--where possession of small quantities for personal use was partially decriminalized, we sought to assess changes over time in knowledge, attitudes, behaviors, and infectious disease profiles among PWID in the adjacent border cities of San Diego, CA, USA, and Tijuana, Baja California, Mexico. Based on extensive binational experience and collaboration, from 2012-2014 we initiated two parallel, prospective, mixed methods studies: Proyecto El Cuete IV in Tijuana (n = 785) and the STAHR II Study in San Diego (n = 575). Methods for sampling, recruitment, and data collection were designed to be compatible in both studies. All participants completed quantitative behavioral and geographic assessments and serological testing (HIV in both studies; hepatitis C virus and tuberculosis in STAHR II) at baseline and four semi-annual follow-up visits. Between follow-up assessment visits, subsets of participants completed qualitative interviews to explore contextual factor relating to study aims and other emergent phenomena. Planned analyses include descriptive and inferential statistics for quantitative data, content analysis and other mixed-methods approaches for qualitative data, and phylogenetic analysis of HIV-positive samples to understand cross-border transmission dynamics. Investigators and research staff shared preliminary findings across studies to provide feedback on instruments and insights regarding local phenomena. As a result, recruitment and data collection procedures have been implemented successfully, demonstrating the importance of binational collaboration in evaluating the impact of structural-level drug policy reforms on the behaviors, health, and wellbeing of PWID across an international border. Our prospective, mixed methods approach allows each study to be responsive to emerging phenomena within local contexts while regular collaboration promotes sharing insights across studies. The strengths and limitations of this approach may serve as a guide for other evaluations of harm reduction policies internationally.
    Harm Reduction Journal 02/2014; 11(1):4. DOI:10.1186/1477-7517-11-4 · 1.26 Impact Factor
  • Source
    • "Even in 2011, members of the U.S. Congress demonize such organizations as Planned Parenthood that advocate pregnancy and HIV/STD prevention, empowering the poor and the young to access their unmet needs for these services. The failure to promptly, consistently , and extensively provide clean needles and syringes for IDUs (and for health care in resource-limited settings) led to an estimated 4394 to 9666 preventable infections in the U.S. alone (33% of the incidence in IDUs) from 1987 to 1995, costing society US$244 to US$538 million (Lurie and Drucker 1997). The U.S. Federal Government did not lift its ban on funding for needle/syringe exchange programs (N/SEP) until 2009, despite overwhelming evidence indicating its effectiveness in preventing HIV transmission. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The HIV epidemic in higher-income nations is driven by receptive anal intercourse, injection drug use through needle/syringe sharing, and, less efficiently, vaginal intercourse. Alcohol and noninjecting drug use increase sexual HIV vulnerability. Appropriate diagnostic screening has nearly eliminated blood/blood product-related transmissions and, with antiretroviral therapy, has reduced mother-to-child transmission radically. Affected subgroups have changed over time (e.g., increasing numbers of Black and minority ethnic men who have sex with men). Molecular phylogenetic approaches have established historical links between HIV strains from central Africa to those in the United States and thence to Europe. However, Europe did not just receive virus from the United States, as it was also imported from Africa directly. Initial introductions led to epidemics in different risk groups in Western Europe distinguished by viral clades/sequences, and likewise, more recent explosive epidemics linked to injection drug use in Eastern Europe are associated with specific strains. Recent developments in phylodynamic approaches have made it possible to obtain estimates of sequence evolution rates and network parameters for epidemics.
    Cold Spring Harbor Perspectives in Medicine 05/2012; 2(5):a007195. DOI:10.1101/cshperspect.a007195 · 9.47 Impact Factor
Show more


13 Reads